From professional translators, enterprises, web pages and freely available translation repositories.
a16ax06 ttreatment of mild to moderate type 1 gaucher disease when enzyme replacement therapy is unsuitable
disease when enzyme replacement therapy is unsuitable
concept paper on the development of a points to consider on xenogeneic cell therapy verabschiedet im november 2000
treatment of erythema nodosum leprosum or type ii reactions in hansen’ s disease
single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:
single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women:
concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of b iotechnology-derived products
documento concettuale concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology-derived products
titel des dokuments antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
titolo del documento antimicrobials for general use in target animal species summary of product characteristics for antimicrobial products efficacy requirements for ectoparasiticides for cattle fluid therapy
zur behandlung der hyperurikämie ist eine entsprechende harnsäuresenkende therapie (urate lowering therapy; ult) einzuleiten oder zu optimieren.
la gestione dell’iperuricemia deve essere iniziata oppure ottimizzata con una appropriata terapia uricosurica (ult).
im pro jekt "cell therapy" entwickeln fünf partner aus norwegen, großbritannien, der schweiz und deutschland neue therapeutische ansätze für gehirnkrebs.
il progetto "cell therapy", a cui stanno lavorando cinque partner della norvegia, del regno unito, della svizzera e della germania, sta mettendo a punto nuovi approcci terapeutici per curare il tumore al cervello.
duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing) safety studies for gene therapy products.
duration of chronic toxicity testing in animals (rodent and non-rodent toxicity testing)
health assessment questionnaire (haq) 3 functional assessment of chronic illness therapy-fatigue (facit-f)
mtx, questionario di valutazione dello stato di salute (haq), valutazione funzionale della terapia delle malattie croniche (facit-f)
b) the scientific environment (number of validated biomarkers, new or amended guideline rules, evolution of average length of time for therapy approval).
b) indicatori che misurano l'impatto dell'imi sull'ambiente scientifico (numero di biomarcatori convalidati, linee guida normative nuove o modificate, evoluzione del tempo medio ad approvazione da area terapeutica).
in diesen studien wurde bei 507 patienten die empfohlene dosierung von 400 mg zweimal täglich in kombination mit einer optimierten hintergrundtherapie (optimized background therapy, obt) im vergleich zu 282 patienten unter plazebo in kombination mit obt angewendet.
in questi studi è stato utilizzato il dosaggio raccomandato di 400 mg due volte al giorno in associazione con la terapia di base ottimizzata (obt) in 507 pazienti, confrontati con 282 pazienti che hanno assunto placebo in associazione con la obt.
eine besserung des erschöpfungszustandes, gemessen anhand des „functional assessment of cancer therapy- fatigue“ (fact-fatigue) scores, wurde ebenfalls beobachtet.
È stato inoltre osservato un miglioramento nell’affaticamento, misurato con la scala functional assessment of cancer therapy – fatigue (fact – fatigue).